Seth Klarman Purchases 18% Stake in Targacept

Seth Klarman Purchases 18% Stake in Targacept

Seth Klarman Purchases 18% Stake in Targacept

In a 13-D just filled with the SEC, Baupost has disclosed a 9% stake in Targacept. What is very unusual is that Seth Klarman personally also bought a 9% stake as well. After years of following Seth Klarman’s Baupost, we have never seen him buy a personal stake in a company.

This is a usual Klarman buy, an esoteric bio-tech company, which is hard to value or understand.

This Tiger grand-cub was flat during Q2 but is ready for the return of volatility

Tiger Legatus Master Fund was up 0.1% net for the second quarter, compared to the MSCI World Index's 7.9% return and the S&P 500's 8.5% gain. For the first half of the year, Tiger Legatus is up 9%, while the MSCI World Index has gained 13.3%, and the S&P has returned 15.3%. Q2 2021 hedge Read More

Below is a brief description:

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. Its lead program, TC-5214, a nicotinic channel modulator, is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder (MDD) and in Phase 2b clinical trial for switch monotherapy in patients with MDD. The company?s novel small molecule product candidates under Phase 2 clinical development include TC-5619 for treating negative symptoms and cognitive dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and Alzheimer?s disease; AZD3480 as a treatment for mild to moderate Alzheimer?s disease; AZD1446 as a treatment for Alzheimer?s disease; and TC-6987 for the treatment of inflammatory disorders, including asthma and Type 2 diabetes. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

The company has a market cap of $200million.

More details to follow.

Full filling-


No posts to display